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Neuromuscular disorders with defects in the mito-
chondrial ATP-generating system affect a large
number of children and adults worldwide, but remain
without treatment. We used a mouse model of mito-
chondrial myopathy, caused by a cytochrome c oxi-
dasedeficiency, toevaluate theeffectof inducedmito-
chondrial biogenesis on the course of the disease.
Mitochondrial biogenesiswas inducedeitherby trans-
genic expression of peroxisomeproliferator-activated
receptor g (PPARg) coactivator a (PGC-1a) in skeletal
muscle or by administration of bezafibrate, a PPAR
panagonist. Both strategies successfully stimulated
residual respiratory capacity in muscle tissue.
Mitochondrial proliferation resulted in an enhanced
OXPHOS capacity per muscle mass. As a conse-
quence, ATP levels were conserved resulting in a de-
layedonsetof themyopathyandamarkedlyprolonged
life span. Thus, induction of mitochondrial biogenesis
through pharmacological or metabolic modulation of
the PPAR/PGC-1a pathway promises to be an effec-
tive therapeutic approach formitochondrial disorders.
INTRODUCTION
Alterations of both nuclear and mitochondrial DNA (mtDNA) are
associated with defects in the oxidative phosphorylation (OX-
PHOS) system. With an incidence of 1:5000, mitochondrial
disorders are one of the most common inherited neuromuscular
diseases (Schaefer et al., 2008). Current treatments of mitochon-
drial diseases address the symptoms but not the deficiency itself
(DiMauro andMancuso, 2007). One possible approach to relieve
the deficiency might be to boost the residual OXPHOS capacity
by increasing the mitochondrial functional mass in the affected
tissues.
The peroxisome proliferator-activated receptors (PPARs) are
a subfamily of the nuclear receptors, a group of ligand-modu-
lated transcription factors that regulate gene-expression pro-
grams of metabolic pathways. The role of PPARa and PPARd
in modulating fatty acid oxidationmade them therapeutic targetsCellfor the treatment of hyperlipidemia, diabetes, andmetabolic syn-
drome (Mensink et al., 2007). Activation of PPARd also resulted
in increased mitochondrial mass and enhanced mitochondrial
function (Wang et al., 2002). Recently, it has been shown that
modulating the activity of PPARs by certain synthetic agonists
in mouse and human cells increases OXPHOS capacity (Bastin
et al., 2008; Hondares et al., 2007). Mitochondrial biogenesis is
modulated by PPARg coactivator a (PGC-1a), a transcriptional
coactivator of nuclear receptors and other transcription factors,
including nuclear respiratory factors (NRF1 andNRF2) and estro-
gen-related receptor alpha (ERRa) (Mootha et al., 2004;
Schreiber et al., 2004; Wu et al., 1999). It also affects mtDNA
levels by modulating transcription of the mtDNA transcription
factor A (Tfam) gene (Handschin and Spiegelman, 2006).
In this work, we addressed the question of whether increasing
mitochondrial biogenesis via PPAR/PGC-1a pathways would
improve clinical symptoms of a mitochondrial myopathy.
RESULTS
Increased Expression of PGC-1a Delays the Onset
of a Mitochondria Myopathy in Mice
In our mouse model, the COX10 gene, which encodes for an es-
sential cytochrome oxidase (COX) assembly factor (Barros and
Tzagoloff, 2002), is ablated in skeletal muscle using the Cre-
LoxP system. In this conditional knockout mouse, Cre recombi-
nation occurs over time in the muscle nuclei, resulting in a partial
and segmental COX deficiency. Because muscle fibers are
multinucleated and the gene ablation occurs over time, the
COX deficiency also increases during this period, resulting in
a progressive myopathy (Diaz et al., 2005). This segmental and
progressive pattern of the defect is a common feature in human
mitochondrial myopathies (Schaefer et al., 2008), making this
model useful to test potential therapeutic approaches. Two dif-
ferent muscle-specific transgenic Cre recombinases were used
in this study. Expression of the Cre recombinase from the
Mlc1f promoter resulted in a mitochondrial myopathy (hereafter
referred to as the ‘‘severe myopathy model’’), characterized by
weight loss, increased number of falls on a treadmill at 2.5–3
months, and premature death at 3–4 months of age (Diaz
et al., 2005). Expression of the Cre recombinase from the
Mef2c promoter caused a milder phenotype resulting in death
at 6 months (hereafter referred to as the ‘‘mild myopathyMetabolism 8, 249–256, September 3, 2008 ª2008 Elsevier Inc. 249
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PGC-1a Ameliorates a Mitochondrial MyopathyFigure 1. Longer Life Span and Delayed Onset of the Myopathy Coincide with Improved COX Activity in Muscle Homogenates of PGC-
1aDCOX10 Mice
(A) Survival curve of female PGC-1aDCOX10 mice in comparison to DCOX10 mice (n = 20 for each group). No mice of the PGC-1a and wild-type control groups
died in the observed timeframe.
(B) Treadmill performance test at different ages for female PGC-1aDCOX10, DCOX10, PGC-1a, and wild-type mice (n = 6 for each group). One-way ANOVA,
followed by post hoc Tukey analyses, showed significance between DCOX10 and each of the other groups (bars represent SD).
(C) COX activity of female PGC-1aDCOX10, DCOX10, PGC-1a, and wild-type mice at different ages comparing muscle homogenates and muscle mitochondria
(n = 3 for each group and bars represent SD).
(D) Western blot of COXI, SDH, and tubulin in muscle homogenates and mitochondria of 3-month-old female PGC-1aDCOX10, DCOX10, PGC-1a, and wild-type
mice. COXI levels were below the detection limit of the assay in some samples.250 Cell Metabolism 8, 249–256, September 3, 2008 ª2008 Elsevier Inc.
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PGC-1a Ameliorates a Mitochondrial Myopathymodel’’). A mouse that transgenically expresses PGC-1a in mus-
cle (Lin et al., 2002) was crossed to the two myopathy models to
analyze the effect of induced mitochondrial biogenesis on the
course of the disease.
The difference in severity correlated with the rate of deletion of
the floxed COX10 gene. This gene inactivation was analyzed by
abiplexPCRapproach,asdescribed (Diazetal., 2008) (seeFigures
S1A–C online). Unchanged COX10 deletion in PGC-1aDCOX10
compared to DCOX10 showed that PGC-1a expression did not
interfere with the COX10 ablation (Figures S1D and S1E). We
observed increased COX10 ablation over time (Figure S1D).
In both mouse models, expression of the PGC-1a transgene
dramatically affected the survival of the myopathy mice with
a more beneficial effect seen in females. Female DCOX10 mice
died prematurely before reaching 5 months of age in the severe
myopathy model. In contrast, approximately 50% of the female
PGC-1aDCOX10 lived up to at least one year, surviving their
DCOX10 littermates by 9 months or more (Figure 1A). In fact,
three out of ten female PGC-1aDCOX10 mice lived up to 22
months, which represents a 3.53 longer life span compared to
the disease controls. None of the male DCOX10 mice lived lon-
ger than 6 months. In contrast, more than 50% of the male
PGC-1aDCOX10 mice were alive at 8–9 months, and several
lived up to 12 months (Figure S2A). A similar beneficial effect
of the transgenic PGC-1a expression was seen in the context
of the mild myopathy; all DCOX10 mice died before reaching 6
months of age, whereas all of the PGC-1aDCOX10 mice were
still alive at 9 months (data not shown).
Onset of the disease was monitored by performance on
a treadmill. In both mouse models, DCOX10 showed increased
number of falls on a treadmill test at 3 months of age, indicating
the onset of the myopathy. PGC-1aDCOX10 mice did not show
any impairment of performance on the treadmill test until 7
months of age, showing at least a doubling of the asymptomatic
period (Figures 1B for females, S2B for males, and S3A for
mef2c-Cre). Importantly, even after the onset of the disease, as
judged by treadmill performance, PGC-1aDCOX10 mice stayed
alive for several months, which contrasts with the DCOX10mice,
where premature death occurred within weeks after the onset of
the disease.
PGC-1aDCOX10 Mice Have Increased COX
Activity per Muscle Volume
In muscle homogenates of the severe myopathymodel, COX ac-
tivity in the DCOX10 mice was approximately 20%–40% that of
the wild-type control. In the mild myopathy model, COX activity
in the DCOX10 mice was decreased to 40% of the wild-type
control by 3 months. At 3 months of age, expression of the
PGC-1a in either myopathy model increased the COX activity/
muscle protein essentially to wild-type levels (Figures 1C,
S2C,and S3B). After 7 months of age, the COX activity/muscle
protein in PGC-1aDCOX10 mice decreased in both genders
(Figure 1C). This decrease correlated with increased falls in the
treadmill test indicating the onset of themyopathy. At 12months,
female PGC-1aDCOX10 showed COX activity/muscle protein
that was similar to 3-month DCOX10 mice (Figure 1C). In bothCell Manimal models, the COX activity in isolated muscle mitochondria
of PGC-1aDCOX10 mice was comparable to the DCOX10 mice
at all ages (20%–25% of the wild-type control; Figures 1C,
S2C, and S3B), showing that the increased COX activity in ho-
mogenates resulted from an increased mitochondrial mass/
muscle mass. The COX activity in isolated muscle mitochondria
of PGC-1aDCOX10 mice was comparable to the DCOX10 mice
at all ages (20%–25% of the wild-type control; Figures 1C,
S2D, and S3B).
Western blot analysis of both muscle homogenates and mus-
clemitochondria were in agreement with these results. When an-
alyzing muscle mitochondria (both in DCOX10 and PGC-1aD
COX10), COX I was below the detection limit in mice with the
severe myopathy (Figure 1D). Only after overexposure, a faint
band was visible for both PGC-1aDCOX10 and DCOX10 (data
not shown). In mice with the mild myopathy, COX I could be de-
tected as a weak band. (Figure S3C). In muscle homogenates of
PGC-1aDCOX10 however, we observed a band with intensity
similar to the wild-type control (Figures 1D and S3C).
Histological analysis of the biceps femoris of 3-month-old
PGC-1aDCOX10 mice in both myopathy models showed no
COX-deficient fibers as estimated from the COX and combined
succinate dehydrogenase (SDH)/COX activity staining. At
the same age, DCOX10 mice showed a large number of COX-
deficient fibers (Figures 1E and S3D). At 7 months of age,
PGC-1aDCOX10 mice showed a significant amount of COX-
deficient fibers, but the overall COX deficiency was less severe
than in the 3-month-old DCOX10 mice. At 12 months of age,
60%–70% of the PGC-1aDCOX10 mice muscle fibers were
COX negative. The remaining fibers showed a very intense
COX staining indicating high COX activity (Figure 1E).
PGC-1aDCOX10 Mice Maintain Wild-Type ATP Levels
The rescue of the COX activity in muscle homogenates in the
PGC-1aDCOX10 mice indicated increased mitochondrial prolif-
eration. We further investigated the degree of the increased
mitochondrial biogenesis by measuring the activity of citrate
synthase (CS), a mitochondrial matrix protein. At all ages exam-
ined, the CS activity in PGC-1aDCOX10 mice was 4- to 5-fold
higher than that observed in wild-type controls. The DCOX10
mice showed an increased of CS activity of 2- to 3-fold. CS ac-
tivity normalized to mitochondrial proteins remained unchanged
(Figures 2A and S3E). Other respiratory-chain complexes
showed a similar increase in the activity of homogenates (data
not shown).
We used western blot analysis to determine whether the ex-
pression of various mitochondrial proteins was increased by
the transgenic expression of PGC-1a. In both animal models,
the levels of SDH were elevated 2- to 2.5-fold in homogenates
from mice expressing PGC-1a. Steady- state levels of FoF1-
ATPase were increased 1.5-fold, and the signal for a complex
I subunit ND39 was increased 1.5- to 2-fold. When normalized
to mitochondrial mass, the levels of all examined mitochondrial
proteins remained unchanged (Figures S3C and S4A).
EM analysis of the biceps femoris showed increased mass of
abnormally shaped mitochondria penetrating the myofibrillar(E) Histology of the biceps femoris muscle from female mice at different ages (203magnification) showing the development of the COX deficiency in PGC-1aD
COX10 mice in comparison to a myopathic DCOX10 and to PGC-1a and wild-type mice as controls. SDH, COX, and combined COX/SDH staining are shown.etabolism 8, 249–256, September 3, 2008 ª2008 Elsevier Inc. 251
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PGC-1a Ameliorates a Mitochondrial Myopathyapparatus in the DCOX10 muscle sample. In the samples from
control mice expressing PGC-1a, mitochondria were signifi-
cantly enlarged compared to the wild-type samples but were
found between the individual myofibers, preserving the myofi-
brillar architecture (Figure 2B). Southern blot analysis of genomic
muscle DNA showed that mtDNA levels were increased in mice
expressing PGC-1a (Figure 2C).
In agreement with the findings of an increased mitochondrial
mass and increased activity of respiratory enzymes, we found
that ATP levels in skeletal muscle of 3-month-old PGC-1aD
COX10 were comparable to wild-type controls, whereas the
ATP levels in the DCOX10 were significantly decreased (Figures
2D and S3F).
The maintenance of wild-type ATP levels was reflected in an
endurance exercise test.DCOX10mice ran up to 110m (females)
and 140 m (males). PGC-1aDCOX10mice behaved comparably
to the wild-type and ran for 370 m (females) and 385 m (males).
Mice expressing PGC-1a without a myopathy were able to run
up to 580 m (Figures S2E and S4B), in agreement with recent lit-
erature, where these PGC-1a transgenic mice were reported to
have higher exercise capacity (Calvo et al., 2008).
Figure 2. Increased Mitochondrial Mass in Mice
Expressing PGC-1a
(A) CS activity as a mitochondrial marker in muscle
homogenates and muscle mitochondria from female
PGC-1aDCOX10, DCOX10, PGC-1a, and wild-type mice
at different ages (bars represent SD).
(B) Electron micrograph from longitudinal section taken
from biceps femoris muscle from 3-month-old female
PGC-1aDCOX10, DCOX10, PGC-1a, and wild-type
mice. Mitochondria are indicated by black arrows. Scale
bars represent 2 mm.
(C) RelativequantificationofmtDNAversusnuclearDNAby
signal intensity ofmtDNA and 18S bands in a Southern blot
of DNA isolated from skeletal muscle from 3-month-old fe-
male PGC-1aDCOX10, DCOX10, PGC-1a, and wild-type
mice (n = 3 for each group and bars represent SD).
(D) Quantification of ATP in the biceps femoris muscle from
3-month-old female PGC-1aDCOX10, DCOX10, PGC-1a,
andwild-typemice (n =4 for eachgroupandbars represent
SD).
Bezafibrate Delays the Onset
of the Mitochondrial Myopathy
The transgenic approach showed that in-
creased mitochondrial proliferation in muscle
delayed the onset of a mitochondrial myopathy
caused by a COX deficiency. In a second ap-
proach, we addressed the question of whether
increased mitochondrial biogenesis could be
triggered by administration of a drug that stimu-
lates the PPARs/ PGC-1a pathways. It has been
recently shown that bezafibrate, a PPAR pana-
gonist, enhances lipid metabolism and oxida-
tive capacity (Bastin et al., 2008; Tenenbaum
et al., 2005). Therefore, we fed our DCOX10
a diet containing 0.5% bezafibrate starting at 5
weeks of age. As a control, DCOX10 and wild-
type animals were fed a regular diet.
We could not detect any difference in the levels of tissues
enzymes in serum between the animals that were treated with
bezafibrate and the animals on the regular diet, suggesting that
bezafibrate did not cause tissue damage in the observed time
frame (data not shown).
Bezafibrate-fed DCOX10 mice lived significantly longer than
their DCOX10 littermates on a regular diet. Whereas the latter
died around 3–4 months, all of the observed DCOX10 animals
on the bezafibrate diet reached at least 6 months of age
(Figure 3A). No difference in survival was observed in the wild-
type control animals on the bezafibrate diet compared to the
wild-type animals on a regular diet (data not shown).
Disease onset was monitored by treadmill performance. The
bezafibrate-fed DCOX10 mice behaved similarly to the wild-
type at this age, and at 6 months, showed a better treadmill per-
formance than the regular-fed DCOX10 at 3 months (Figure 3B).
Bezafibrate Partially Rescues the COX Deficiency
in DCOX10 Muscle Tissue
The COX activity in muscle homogenates of the bezafibrate-fed
DCOX10 animals was 4-fold higher when compared to252 Cell Metabolism 8, 249–256, September 3, 2008 ª2008 Elsevier Inc.
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PGC-1a Ameliorates a Mitochondrial MyopathyFigure 3. Bezafibrate Administration to DCOX10 Mice Induces PGC-1a Expression in Skeletal Muscle Resulting in Delayed Onset
of the Myopathy
(A) Survival curve of female DCOX10 on the bezafibrate diet mice in comparison to DCOX10 mice on a regular diet (n = 7 for each group). No mice in wild-type
groups (bezafibrate diet or regular diet) died in the observed time frame.
(B) Treadmill performance test at different ages for DCOX10 and wild-type mice on a bezafibrate diet. DCOX10 and wild-type mice on a regular diet were used as
reference (n = 3 for each group and bars represent SD). At the 3 months’ time point, statistical significance was reached between DCOX10 on the standard diet
and each of the other groups. At the 6 months’ time point, significance was reached between DCOX10 on the bezafibrate diet and each of the other groups.
(C) COX activity and CS activity inmuscle homogenates of 3-month-old femaleDCOX10 andwild-typemice on a bezafibrate and regular diet (n = 3 for each group
and bars represent SD).
(D) Histology of the biceps femoris muscle from 3-month-old female mice showing DCOX10 and wild-type mice on a bezafibrate and regular diet. SDH staining is
shown to indicate the mitochondrial proliferation. COX and combined COX/SDH staining highlight the degree of COX deficiency.
(E) Quantification of ATP in the biceps femoris muscle from 3-month-old DCOX10 and wild-type mice on a bezafibrate and regular diet (n = 2 for each group and
bars represent range).
(F) Relative expression of PGC-1a, PGC-1b, and PPARa/d and g in skeletal muscle of 3-month-old female DCOX10 and wild-type mice on a bezafibrate diet.
DCOX10 and wild-type mice on a regular diet were used as reference (n = 3 and bars represent SD).Cell Metabolism 8, 249–256, September 3, 2008 ª2008 Elsevier Inc. 253
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the activity of wild-type mice on a regular diet. At the mitochon-
drial level, the COX deficiency was unaffected by the bezafibrate
administration (Figure S5A). The COX activity in muscle homog-
enates of the bezafibrate-fed wild-type mice was also increased
compared to wild-type animals on the regular diet (Figure 3C).
Western blot analysis of muscle homogenates and muscle
mitochondria correlated with the rescue of the COX activity in
the bezafibrate-fed mice. COX I levels were below detection in
muscle mitochondria in all DCOX10 mice (regular and bezafi-
brate diet) (Figure S5B). However, in muscle homogenates, the
signal for COX I in the bezafibrate-fed DCOX10 was 75% of
the wild-type level (Figure S5C).
Histological analyses were in agreement with these findings.
The biceps femoris of the bezafibrate-fed DCOX10 at 3 months
showed less COX-deficient fibers than the DCOX10 on a regular
diet. The wild-type animals on the bezafibrate diet lost the char-
acteristic checkerboard pattern (Figure 3D). A similar pattern
was observed for the transgenic PGC-1a mice (Figure 1E).
Bezafibrate Raises ATP Levels in Skeletal Muscle
by Increasing Mitochondrial Biogenesis
The partially rescued COX activity in muscle homogenates of be-
zafibrate-fed DCOX10 animals indicated that the drug increased
mitochondrial biogenesis. To analyze the degree of mitochon-
drial proliferation, we examined the steady-state levels of differ-
ent mitochondrial proteins. Western blot analysis showed that
SDH levels were increased by 2- to 2.5-fold in muscle of beza-
fibrate-fed animals. FoF1-ATPase was increased by 1.5-fold,
and complex I increased by 1.5- to 2-fold, as judged from in-
creased intensity of the ATPaseb and ND39 bands, respectively
(Figure S5C).
The activity of CS was increased 2.5-fold in muscle homo-
genates of bezafibrate-fed mice compared to wild-type animals
on a regular diet, indicating increased mitochondrial proliferation
(Figure 3C). In agreement, we also observed an increase in
mtDNA levels in bezafibrate-fed animals (Figure S5D). We found
that ATP levels in skeletal muscle of 3-month-old bezafibrate-fed
DCOX10 animals were increased compared to the DCOX10 on
a regular diet and maintained80% of the wild-type values (Fig-
ure 3F). This increased energy supply of the bezafibrate-fed
DCOX10mice was reflected in the improved endurance exercise
test. Whereas DCOX10 on a regular diet could only run 100 m
until exhaustion, bezafibrate-fed DCOX10 stayed on the tread-
mill for up to 280 m. Wild-type animals on the bezafibrate diet
also showed a higher endurance than the wild-type mice on
the regular diet (480 m versus 380 m; Figure S5E).
The mechanism of phenotypic suppression appears related
to PGC-1a-induced mitochondrial biogenesis. We found that
all three PPARs and PPAR coactivators were upregulated by
administration of bezafibrate (Figure 3F).
DISCUSSION
In this study, we have used the targeted deletion of the COX 10
assembly factor as a model of mitochondrial myopathy to inves-
tigate whether induced mitochondrial biogenesis can delay the
disease onset by stimulating residual OXPHOS capacity. The
rationale for this hypothesis is based on the natural history of254 Cell Metabolism 8, 249–256, September 3, 2008 ª2008 Elseviermitochondrial diseases. Mitochondrial proliferation is commonly
observed in affected tissues of patients withmitochondrial disor-
ders, and it is believed to be a compensatory mechanism
triggered by the OXPHOS defect (Rossmanith et al., 2008).
Mitochondrial biogenesis in mice was triggered either by
transgenic expression of PGC-1a in muscle (Lin et al., 2002) or
by pharmacological activation of the PPAR pathway through
administration of bezafibrate (Bastin et al., 2008; Hondares
et al., 2007).
Both approaches—transgenic PGC-1a and bezafibrate ad-
ministration—benefited DCOX10 animals, resulting in a longer
life span and a delayed onset of the myopathy. The beneficial
effect was likely due to an increased mitochondrial mass as
evident from elevated mitochondrial protein levels and enzyme
activity in the muscle tissue. This increased mitochondrial
biogenesis optimized the residual COX activity resulting in
enhanced COX steady-state levels and COX activity/muscle
mass. The bezafibrate administration started at 5 weeks of
age, only a few weeks before the initial symptoms of the myop-
athy in the DCOX10mice (2.5–3 months). This contrasts to the
transgenic PGC-1a expression, where mitochondrial biogenesis
is induced before the defect starts. Interestingly, bezafibrate
treatment starting shortly before the myopathy onset was highly
beneficial in reducing the myopathy and prolonging life span.
Why is the natural compensatory mechanism (ragged-red
fiber formation) inefficient when compared to induced PGC-1a
expression? The increased mitochondrial proliferation in af-
fected muscles of patients or mouse models appears restricted
to OXPHOS-deficient fibers. On the other hand, induced expres-
sion of PGC-1a leads to the increased biogenesis of all mito-
chondria, including OXPHOS-competent organelles, leading to
a functional improvement at the muscle level. In addition,
although increased mitochondrial proliferation was observed in
muscle of the DCOX10 animals (Diaz et al., 2005 and above), it
showed a different intratissue distribution than that induced by
PGC-1a. In theDCOX10 samples, we observed clusters of small,
round mitochondria penetrating the myofibrillar structure, a fea-
ture that might contribute to the rapid progression of the myop-
athy. PGC-1a-induced expression resulted in preferential prolif-
eration of enlarged mitochondria, which were lined up between
myofibrils without interfering with the muscle structure.
A beneficial effect of PGC-1a overexpression in muscle has
been observed in a mouse model of Duchenne muscular dystro-
phy (Handschin et al., 2007b). Therefore, the overall improved
muscle metabolism could also have an important role in the pos-
itive effect observed. It is important to note that PGC-1a has
been shown to have other beneficial effects in muscle tissues
in addition to mitochondrial biogenesis, including the suppres-
sion of inflammation (Handschin et al., 2007a), the induction of
certain structural proteins affecting fiber integrity (Handschin
et al., 2007b), and increases in angiogenesis (Arany et al.,
2008). How these nonmitochondrial pathways influence the
health and life span of the myopathy mice is not clear but cannot
be ruled out.
In conclusion, we showed that stimulation of residual OXPHOS
capacity in skeletal muscle of mice with a mitochondrial
myopathy has a strong therapeutic benefit. The mechanism
involved appears to be an increase in the functional OXPHOS
unit/muscle mass (Figure 4A). This can be achieved byInc.
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mized assembly of OXPHOS complexes. We believe that a
similar strategy can also be effective for most mitochondrial dis-
eases. The defects observed in mitochondrial disease patients
are invariably associated with partially functional OXPHOS. Acti-
vation of PGC-1a/PPARsmight also ameliorate diseases caused
by mtDNA mutations (Figure 4B). Increasing the levels of these
defective proteins or improving assembly via the PGC-1a/
PPARs pathway might overcome the defect and enhance
OXPHOS and ATP production due to mutations in the nuclear
DNA (Figure 4C). Thus, controlling the expression of PGC-1a
and the PPARs might offer a novel treatment strategy not only
to mitochondrial myopathies, but also other mitochondrial dis-
eases. The promising results with the bezafibrate-fed myopathy
mice clearly identify small-molecule PPAR agonists, already
used in humans with metabolic disorders as a treatment option
for mitochondrial diseases.
EXPERIMENTAL PROCEDURES
Generation of PGC-1a DCOX10 Mice
Mice carrying a floxedCOX10 gene and themuscle-specific deletion of COX10
using a mlc-Cre recombinase were created in our laboratory as described
(Diaz et al., 2005). The mice expressing PGC-1a in skeletal muscle was previ-
Figure 4. Model for the Potential Role of PGC-1a for the
Treatment of Mitochondrial Disease
(A) Animal model of mitochondrial myopathy. Muscle fibers in the
DCOX10 mice have different degrees of COX10 deletion and
mitochondria with variable OXPHOS capacity. PGC-1a expression-
induced mitochondrial biogenesis enriches all mitochondria popula-
tions resulting in an increased number of OXPHOS competent units/
muscle fiber and increased ATP levels.
(B) Mitochondrial disease patient with mutation in mtDNA. Muscle
fibers are heteroplasmic for the mtDNA mutation resulting in mito-
chondria with different levels of OXPHOS activity. During ragged-red
fiber (RRF) formation, mitochondria carrying the mutation are en-
riched. PGC-1a expression-induced mitochondrial biogenesis might
enrich all mitochondria populations resulting in an increased number
of OXPHOS competent units/muscle fiber and increased ATP levels.
(C) Mitochondrial disease patient with mutation in nDNA. Muscle
fibers have mitochondria with residual OXPHOS activity. PGC-1a
expression-induced mitochondrial biogenesis might increase the mi-
tochondrial mass resulting in an increased OXPHOS capacity/muscle
fiber and increased ATP levels.
ously described (Lin et al., 2002). The transgenice mef2c-Cre animals
were obtained from Dr. Brian L. Black at UCSF. DCOX10 mice were
started on a bezafibrate diet (regular diet containing 0.5% bezafibrate,
Bioserv) at 5 weeks of age.
Blood Work
Blood was withdrawn from deeply anesthesized animals by cardiac
puncture. Serum was obtained, and the levels of liver, kidney, pan-
creas enzymes, and creatine phosphokinase were determined by
the Comparative Pathology Laboratory at the University of Miami,
Miller School of Medicine.
Treadmill Experiment
Mice were run on a treadmill (Columbus Instruments, Columbus, OH)
set at 8 m/min for 2min. Performance wasmeasured by the number of
times a mouse failed to stay in the running belt and fell into the moti-
vational grid.
To determine exercise capacity under an endurance paradigm, 3-month-old
mice were placed on the treadmill and run with a fixed slope of 10. During the
first 3 min, the speed was 6.5 m/min and increased 0.5 m/min every 3 min
thereafter. The protocol is shown schematically in Figure 1D. Animals ran until
exhaustion, which is defined by >10 falls/min into the motivational grid.
Isolation of Mitochondria and Measurement of RC-Complex Activity
Mitochondrial preparations were obtained as described (Diaz et al., 2005)
and stored at 80C until needed. Muscle homogenates were prepared
by homogenizing a snap-frozen muscle piece (50 mg) in 500 ml of 10 mM
HEPES (pH 7.4), 0.5 mM EDTA, 0.5 mM EGTA, and 250 mM sucrose and
used immediately. Enzyme activities were determined spectrophotometrically
as described (Diaz et al., 2005). Protein concentrations were estimated by the
method of Bradford using bovine serum albumin (BSA) as a standard.
Histochemistry and Electron Microscopy
Muscle tissue was frozen in isopentane liquid nitrogen. Cross-sections (8 mm)
were stained for COX, SDH, and combined activities (Sciacco and Bonilla,
1996). Transmission electron microscopy was performed using standard
procedures (Miller et al., 2001).
Western and Southern Blots
Westernblot analysiswasperformedasdescribedpreviously (Diaz et al., 2005).
Antibodies against different subunits of the OXPHOS complexes and VDAC
were obtained from Molecular Probes (Eugene, OR), and an antibody against
tubulin was obtained from Chemicon International (Temecula, CA). Southern
blot for mtDNA was performed as previously described (Diaz et al., 2002).Cell Metabolism 8, 249–256, September 3, 2008 ª2008 Elsevier Inc. 255
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Animals were anesthetised, and muscle tissue was extracted and immediately
frozen in liquid nitrogen. ATP was extracted from tissues using perchloric acid
as described previously (Vives-Bauza et al., 2007). ATP concentrations were
determined using the luciferase-based Enliten ATP Assay System from Prom-
ega, and values were normalized to mg of tissue.
Real-Time Quantitative PCR
Total RNA was extracted from snap-frozen muscle by TRIZOL (Life Technolo-
gies). cDNA was synthesized using the SuperScript First Strand Kit (Invitro-
gen). Quantitative real-time PCR reactions were performed on the cDNAs in
the presence of fluorescent dye (SYBR Green, QIAGEN). All results are
expressed as means ± SEM. The results were normalized for comparison by
measuring b-actin mRNA levels in each sample.
Statistics
One-way analysis of variance (ANOVA) was performed for the different groups
followed by post hoc pairwise multiple-comparison procedures (Tukey Test).
SUPPLEMENTAL DATA
Supplemental Data include five figures and can be found online at http://www.
cellmetabolism.org/cgi/content/full/8/3/249/DC1/.
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